No grant funding and fewer than five full-time equivalent staff members are hardly the resources one might expect for a ...
Long-acting cabotegravir plus rilpivirine maintained viral suppression in the vast majority of people with HIV who switched ...
More than 6% of newborns living in households with hepatitis B (HBV)-positive contacts are not vaccinated against the virus ...
Young children infected with certain respiratory syncytial virus (RSV) subgroup B lineages experienced greater disease ...
A rapid phenotypic antimicrobial susceptibility testing (AST) platform returned results about 44 hours sooner than standard ...
Antimicrobial resistance directly caused a near $1 trillion loss in human welfare globally in 2021, disproportionately ...
Angela Campbell, MD, MPH, tells us about the best things she’s seen so far at the conference, and what she's excited about in the next 24 hours at IDWeek.
Starting the HPV vaccine series younger substantially increased the share of children who began and finished the series by ...
FDA approves Hibsago for chronic hepatitis B, offering eligible adults without cirrhosis a potential functional cure.
ESCMID and IDSA have released the first batch of new consensus statements on diagnosing and managing Staphylococcus aureus ...
The wait is almost over. Infectious Disease Special Edition’s podcast “Beaten Pathogens,” launches this week. Here is a sneak ...
The oral medication pritelivir (Hovilpri, Asahi Kasei) works for immunocompromised patients with refractory or resistant herpes simplex virus infections, according to a safety analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results